Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy
- 1 July 2006
- journal article
- case report
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (7), 2522-2524
- https://doi.org/10.1128/aac.00148-06
Abstract
Clinical failure associated with reduced susceptibility to caspofungin has been described in Candida albicans and C. parapsilosis . We report a case of Candida krusei infection that progressed despite caspofungin therapy. Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1 .Keywords
This publication has 9 references indexed in Scilit:
- Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse FungiScience, 2005
- Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Sensititre YeastOne Caspofungin Susceptibility Testing of Candida Clinical Isolates: Correlation with Results of NCCLS M27-A2 Multicenter StudyAntimicrobial Agents and Chemotherapy, 2005
- Multiechinocandin- and Multiazole-ResistantCandida parapsilosisIsolates Serially Obtained during Therapy for Prosthetic Valve EndocarditisAntimicrobial Agents and Chemotherapy, 2005
- Comparison of PCR- and HinfI Restriction Endonuclease-Based Methods for Typing of Candida krusei IsolatesJournal of Clinical Microbiology, 2004
- Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus SpeciesJournal of Clinical Microbiology, 2004
- Caspofungin Resistance inCandida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida EsophagitisAntimicrobial Agents and Chemotherapy, 2004
- CaspofunginClinical Infectious Diseases, 2003
- Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitorsAntimicrobial Agents and Chemotherapy, 1997